In our study, we observed similar relative p16INK4a mRNA expression levels in prostate tumor tissues and BPH tissues, along with a significantly decreased relative expression of p16INK4a mRNA in patients with serum PSA levels ≥ 10 ng/ml. The gene discussed is CDKN2A; the disease is benign prostatic hyperplasia.